|1.||McGrath, Donnie: 10 articles (04/2014 - 02/2008)|
|2.||Daar, Eric S: 9 articles (12/2014 - 12/2009)|
|3.||Sax, Paul E: 8 articles (12/2014 - 12/2009)|
|4.||Tierney, Camlin: 7 articles (03/2015 - 12/2009)|
|5.||Haas, David W: 6 articles (09/2015 - 03/2009)|
|6.||McComsey, Grace A: 6 articles (08/2015 - 06/2011)|
|7.||Gathe, Joseph: 6 articles (03/2015 - 09/2011)|
|8.||Ha, Belinda: 6 articles (03/2015 - 05/2008)|
|9.||Farajallah, Awny: 6 articles (01/2015 - 12/2009)|
|10.||Molina, Jean-Michel: 6 articles (03/2014 - 08/2008)|
08/01/2011 - "Switch to atazanavir-containing regimens that were well tolerated resulted in significant improvement of hyperlipidemia and maintenance of clinical, immunologic, and virologic responses to CART."
06/01/2005 - "Switching to atazanavir results in a significant improvement in HIV therapy-induced hyperlipidemia. "
06/01/2009 - "Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir."
08/01/2011 - "In this 48-week prospective, observational study that was conducted at designated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years or older who had developed hyperlipidemia after receiving CART that did not contain atazanavir were enrolled. "
08/01/2011 - "This study aimed to evaluate the clinical, virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART was switched to atazanavir-containing antiretroviral regimens. "
04/01/2012 - "Atazanavir: in pediatric patients with HIV-1 infection."
05/01/2010 - "Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection."
05/29/2009 - "Atazanavir: a review of its use in the management of HIV-1 infection."
11/01/2006 - "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection."
12/01/2004 - "Atazanavir for the treatment of human immunodeficiency virus infection."
06/01/2006 - "Intriguingly, atazanavir, a newer PI equally effective against HIV, is associated with fewer signs of lipodystrophy. "
06/01/2006 - "Individual variations in glucuronation may result in differences in serum concentrations of atazanavir, resulting in lipodystrophy, illustrating the difficulty in adjusting dosage. "
01/15/2006 - "Use of atazanavir for 48 weeks neither resulted in abnormal fat redistribution in antiretroviral-naive patients nor induced other metabolic disturbances commonly associated with HIV-related lipodystrophy. "
05/01/2005 - "Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir."
05/01/2004 - "Does atazanavir cause lipodystrophy?"
|4.||Acquired Immunodeficiency Syndrome (AIDS)
02/01/2015 - "Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A."
12/01/2014 - "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202."
01/01/2007 - "Over 10 years, patients who started on atazanavir had 30 additional AIDS events per 100 patients. "
04/01/2014 - "We used genomewide genotyping and clinical data to characterize determinants of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. "
04/01/2014 - "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202."
|5.||HIV Infections (HIV Infection)
07/01/2004 - "Data on atazanavir for the treatment of HIV infection are limited to several phase II and III trials, one of which is still ongoing. "
02/01/2015 - "Atazanavir (ATV) is an attractive option for the treatment of Pediatric HIV infection, based on once-daily dosing and the availability of a formulation appropriate for younger children. "
06/18/2012 - "Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use."
02/01/2009 - "Role of atazanavir in the treatment of HIV infection."
01/28/2005 - "Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety."
|5.||Protease Inhibitors (Protease Inhibitor)
|8.||lamivudine drug combination abacavir
|9.||RNA (Ribonucleic Acid)
|1.||Highly Active Antiretroviral Therapy (HAART)